Welcome back to Digital Trials Digest — ObvioHealth's quarterly look at what's new in ObvioGo, where the industry is heading, and the partnerships shaping the future of decentralized trials.

Big news: What's new in ObvioGo

This quarter's release delivered meaningful enhancements across participant experience and regulatory compliance, with a strong focus on modern consent and assent workflows:

• Assent support. Dedicated configuration and tracking for minors and dependent participants, with full audit coverage and re-assent capabilities.
• eSignature countersignature. A compliant investigator countersignature workflow for consent activities, with configurable requirements, re-consent triggers, 2FA, and enhanced audit trails.
• Ad Hoc Activity Review. Participants can now view previously submitted Ad Hoc responses directly in the mobile app, improving transparency and reducing duplicate submissions in high-frequency reporting studies.

Company news: Oracle Health and Life Sciences integration

ObvioGo is now directly integrated with Oracle Health and Life Sciences Clinical One Data Collection, extending Oracle's Clinical R&D portfolio with enterprise-grade ePRO, eConsent, and eCOA capabilities in a single, unified clinical trial system. "Being integrated and sold as part of Oracle Health and Life Sciences validates ObvioGo as an enterprise-ready participant technology platform designed to operate at global scale," said Richard Watkins, CRO, ObvioHealth.

Thought leadership: SCOPE 2026

Tim Giacomini and Richard Watkins attended SCOPE 2026, where the throughline across sessions was consistent: the tools exist, the evidence exists, and the gap is operational — exactly the problem ObvioGo was built to address.

Client & partner spotlight: Novotech standardizes on ObvioGo

Novotech, a globally recognized full-service CRO, selected ObvioGo under a strategic multi-trial licensing agreement, making ObvioGo the standardized participant-facing digital layer across its decentralized and hybrid study portfolio. "This partnership with Novotech reflects [our] focus on consistent, scalable digital execution across global programs," said Ivan Jarry, CEO, ObvioHealth.

Coming soon in ObvioGo

Image and file upload within study activities, manual redaction for photo file uploads, and Central Rating for independent expert review of participant-submitted images and files.

Download the full Q2 2026 issue (PDF) → for details, upcoming events, and more.